Live Analyst Rating Changes 16810 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jack Meehan
NEPH

Jack Meehan

Nephron
Wall Street Analyst
★★☆☆☆
#2390
on 13Foresight · ranked by our own returns
52%
Success Rate
+23.7%
Average Return
11 of 21 calls profitable · -1.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 52% of Jack Meehan's ratings turned a profit when each position was held for 1 year — averaging +23.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

1 Buy 4 Hold 0 Sell
Jack's Stock Coverage 20 ratings · 2026-08-02
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
A
Agilent
 Mar 26, 2026 BUY Strong Buy
+7.3% avg upside
33 analysts
$145.00
4.85% Upside
 +22.4% ·
RVTY
Revvity
 Mar 26, 2026 HOLD Buy
-5.3% avg upside
23 analysts
$90.00
19.98% Downside
 +29.3% ·
QGEN
Qiagen
 Jan 21, 2026 HOLD Buy
+1.2% avg upside
24 analysts
$59.00
42.61% Upside
 -24.9% ·
BRKR
Bruker
 Nov 03, 2025 HOLD Strong Buy
-9.2% avg upside
22 analysts
 — +59.5% ·
QDEL
QuidelOrtho
 Jul 09, 2025 HOLD Buy
+134.6% avg upside
13 analysts
$40.00
138.61% Upside
 -44.8% ·
DGX
Quest Diagnostics
 Mar 27, 2025 HOLD Buy
-21.2% avg upside
34 analysts
$184.00
21.05% Downside
 +20.0% ·
WAT
Waters
 Mar 06, 2025 BUY Strong Buy
+0.6% avg upside
30 analysts
$440.00
16.57% Upside
 -21.7% ·
IQV
IQVIA Holdings
 Dec 02, 2024 BUY Strong Buy
+2.6% avg upside
39 analysts
$250.00
6.29% Upside
 +11.8% ·
ICLR
Icon
 Dec 02, 2024 BUY Strong Buy
+15.2% avg upside
26 analysts
$280.00
71.24% Upside
 -14.2% ·
BIO
Bio-Rad Laboratories
 Aug 28, 2024 BUY Strong Buy
+7.4% avg upside
8 analysts
$390.00
19.85% Upside
 -10.7% ·
ILMN
Illumina
 Jun 05, 2024 HOLD Buy
-15.7% avg upside
30 analysts
$100.00
51.32% Downside
 -20.8% ·
PACB
Pacific Biosciences
 Apr 16, 2024 HOLD Buy
+213.7% avg upside
14 analysts
$2.00
42.92% Upside
 -14.3% ·
DHR
Danaher
 Jan 31, 2024 BUY Strong Buy
+8.1% avg upside
45 analysts
$275.00
41.07% Upside
 -6.8% ·
TMO
Thermo Fisher
 Jan 29, 2024 BUY Strong Buy
+4.9% avg upside
38 analysts
 — +2.1% ·
INMD
InMode
 Aug 17, 2020 BUY Buy
+28.4% avg upside
9 analysts
$38.00
151.03% Upside
 +219.9% ·
LH
Labcorp Holdings
 Apr 23, 2020 BUY Strong Buy
-13.0% avg upside
37 analysts
$195.00
36.93% Downside
 +65.3% ·
MTD
Mettler-Toledo
 Mar 26, 2020 HOLD Buy
-17.8% avg upside
18 analysts
$680.00
51.99% Downside
 +76.4% ·
AVTR
Avantor
 Mar 26, 2020 BUY Buy
+12.4% avg upside
26 analysts
$19.00
37.92% Upside
 +136.3% ·
MYGN
Myriad Genetics
 Mar 26, 2020 SELL Hold
+527.8% avg upside
24 analysts
$10.00
249.68% Upside
 -102.2% ·
CRL
Charles River Labs
 Mar 26, 2020 HOLD Strong Buy
-9.3% avg upside
34 analysts
$154.00
33.77% Downside
 +121.5% ·
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jack Meehan — Frequently Asked Questions
How accurate are Jack Meehan's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Jack's ratings were profitable over a one-year hold, with an average return of +23.7% per rating, or +24.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jack ranked on 13Foresight?
Jack Meehan is currently ranked #2390 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jack cover?
Jack most recently has ratings on A, RVTY, QGEN, BRKR, QDEL, DGX, WAT, IQV, ICLR, BIO, ILMN, PACB and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.